No change of breast cancer mortality has been reported previously after long-term hormone replacement therapy. A conceivable explanation for the apparent discrepancy between incidence and mortality may be selection bias due to lower prevalence of breast cancer in women who receive replacement hormones, compared with nonexposed women. We used a new approach to correct for bias due to this ‘healthy drug-user effect,’ by adjusting the external, population-based, mortality rates for such cases prevalent during the recruitment period of our cohort. In this cohort of some 23,000 Swedish women, who were prescribed various hormone replacement regimens, breast cancer mortality was analyzed after follow-up to 12 years. External analyses revealed overall standardized mortality ratios for breast cancer rising from 0.71 to 0.81, but not significantly different from unity, after adjustment procedures. In multivariate regression models, excluding prevalent cases in the cohort, women prescribed estradiol, conjugated estrogens, or an estrogen-progestin combination were not at a higher risk relative to those given other and weak estrogens, relative risks being 0.81 and 0.68, respectively. On the basis of the present analytical approach, we conclude that breast cancer mortality does not appear to be changed overall or in subgroups, despite increased incidence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 15: 1985–90.
Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67–72.
Brinton LA, Hoover R, Fraumeni JFJr. Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 1986; 54: 825–32.
Wingo PA, Layde PM, Lee NC, et al. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987; 257: 209–15. (Erratum published in JAMA 1987; 257: 2438).
Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293–7.
Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832–8.
Hunt K, Vessey M, McPherson K, Coleman M. Longterm surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obster Gynaecol 1987; 94: 620–35.
Jang CP, Daling JR, Band PR, Gallagher RP, White E, Welss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992; 3: 475–9.
Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992; 3: 433–9.
Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C. Combined oestrogen-progestogen replacement and breast cancer risk (Letter). Lancet 1992; 340: 8826.
Bergkvist L, Adami HO, Persson I, Bergström R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130: 2: 221–8.
Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Ob Gyn 1990; 97: 1080–6.
Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75–8.
Pike MC, Bernstein L, Ross RK. Breast cancer and hormone replacement therapy (Letter). Lancet 1989; 335: 297.
Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol II. The Design and Analyses of Cohort Studies. Lyon, France: International Agency for Research on Cancer, 1987; IARC Sci. Pub. No. 82.
Fox AJ, Collier PF. Low mortality rates in industrial cohort studies due to selection for work and survival in the industry. Br J Prev Soc Med 1976; 30: 225–30.
Persson I, Adami HO, Johansson EDB, Lindberg BL, Manell P, Westerholm B. A cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability. Eur J Clin Pharmacol 1983; 25: 625–32.
The Causes of Death Registry, 1988. Official Statisties of Sweden. Stockholm: Statistics Sweden, 1990.
World Health Organization. International Classification of Diseases, Eighth Revision. Geneva: WHO, 1967.
The Cancer Registry. Cancer Incidence in Sweden 1988. Stockholm: National Board of Health and Welfare, 1991.
Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986: 9: 559–63.
Adami HO, Gunnarsson T, Sparén P, Eklund G. The prevalence of cancer in Sweden 1984. Acta Oncol 1989; 28: 463–70.
Frome EL, Checkoway H. Use of Poisson regression models in estimating incidence rates and ratios. Am J Epid 1985; 121: 309–23.
Breslow L, Bailar JC, Brown BW, et al. Measurement of progress against cancer special report. JNCI 1990; 82: 10: 825–35.
Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990; 264: 2648–53.
Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women roceiving hormone replacement therapy. Int J Cancer 1989; 44: 833–9.
Author information
Authors and Affiliations
Additional information
This project is funded in part by grants from the Swedish Cancer Society and from the National Cancer Institute, National Institute of Health, USA.
Rights and permissions
About this article
Cite this article
Yuen, J., Persson, I., Bergkvist, L. et al. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for ‘healthy drug-user’ effect. Cancer Causes Control 4, 369–374 (1993). https://doi.org/10.1007/BF00051340
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00051340